4SC
The development of novel drugs for the treatment of cancer.
Enterprise value
($2m)
Share price
€0.60 VSC.F
Company register number
HRB 132917 (München)
Recent deals
loading funding rounds…
Deutsche Venture Capital(exited)
Wellington Partners(exited)
Santo Holding(exited)
3i Group(exited)
Eurostars SME programme(exited)
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 2 % | (49 %) | 3 % | 522 % | (97 %) | (30 %) | 11 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (367 %) | (581 %) | (818 %) | (54 %) | (2749 %) | (2511 %) | (2234 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (389 %) | (636 %) | (843 %) | (73 %) | (3294 %) | (2710 %) | (2480 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 619 % | 820 % | 140 % | - | - | - |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
